The disabling consequences of Mycetoma

Mustafa Abbas, Peter Siordet Scolding, Abubaker Ahmed Yosif, Roa Fath EL Rahman, Melka O. EL-Amin, Mohamed Kamal Elbashir, Nora Groce, Ahmed Hassan Fahal

1 The Mycetoma Research Centre, University of Khartoum, Khartoum, Sudan, 2 Leonard Cheshire Research Centre, University College London, London, United Kingdom

* ahfahal@hotmail.com, ahfahal@mycetoma.edu.sd

Abstract

Mycetoma is a neglected tropical disease endemic in tropical and subtropical countries, particularly Sudan. The disease is characterised by the triad of painless subcutaneous mass, multiple sinuses and discharge that contain grains. It is a chronic, debilitating disease most commonly affecting the feet or hands and leads to substantial morbidity, loss of function and even amputation. It predominantly affects poor, rural populations and patients typically present late with advanced disease and complications. In this descriptive cross-sectional study, we characterise the disabling consequences of mycetoma. The study included 300 patients; 228 (76%) male and 72 (24%) female with confirmed mycetoma seen at the Mycetoma Research Centre, University of Khartoum, Sudan in the period May 2016 and January 2017. The study design was based upon the International Classification of Functioning, Disability and Health, examining the impact of mycetoma on eight life domains. Our major finding is that mycetoma is a significantly disabling disease. Over 60% of the study population (181 patients) had moderate impairment or difficulty in at least one domain variable. The important disability was mobility impairment and walking difficulty that was reported in 119 patients (39.7%). There was significant pain associated with mycetoma lesions in 103 patients (34%), challenging the traditional view of mycetoma as a painless disease. The economic burden was also found to be substantial, with 126 patients (46.7%) reporting barriers to their ability to sustain themselves. This is the first study evaluating the disabling consequences of mycetoma and shows clear areas for intervention and further research. Options for mitigating social and economic impacts include routine integration of analgesia and physiotherapy into treatment protocols, and adapting educational provision and working practices based on disability assessment. Our data show that mycetoma is a public health issue with direct implications on quality of life.

Author summary

Mycetoma is a neglected tropical disease endemic in many tropical and subtropical countries affecting poor, rural populations. It commonly affects the feet or hands and leads to substantial chronic morbidity, loss of function and disability. The disabling consequences of mycetoma have not been studied before. In this study we interviewed 300 patients and
asked them to what extent mycetoma has affected their lives across several functional domains. We looked at bodily function, mobility, self-care, domestic activities, interpersonal interactions and relationships, education, economic status, and community, social and civic life. We found that mycetoma causes significant disability and pain. It also causes a significant financial burden to patients, interfering with their ability to be economically self-sufficient and to gain remunerative employment. We also found that mycetoma prevents the attainment of education. To overcome mycetoma-related disability we recommend integrating analgesia and physiotherapy into clinical services, adapting educational provision and working practices and early case detection and treatment to avoid the disease disabling consequences.

Introduction

Mycetoma is a neglected tropical disease frequently affecting the poorest of the poor in remote, poor communities [1]. It is endemic in many tropical and subtropical countries around the world including Sudan [2, 3]. The geographical distribution of mycetoma depends on a range of environmental factors such as rainfall, humidity and temperature [4, 5]. Mycetoma has a higher prevalence in rural areas with poor domestic hygiene [6, 7]. The disease is caused by more than 50 microorganisms of fungal or bacterial origin, and hence it is classified as eumycetoma and actinomycetoma respectively [8, 9]. Mycetoma is believed to occur as a result of traumatic implantation of the causative organism into the subcutaneous tissue via minor trauma or injury [10, 11]. It then spreads to involve the skin, deep tissues and bone leading to massive destruction, deformities and disabilities [12, 13]. If untreated it can have a major impact on the affected patients, communities and the health system in endemic countries [14, 15].

The disease is characterised by the triad of subcutaneous mass, multiple sinuses and discharge containing grains [16, 17]. It is most frequently seen in the foot and hand, which account for 86% of reported cases, though no site is exempt [18, 19]. Mycetoma is most prevalent amongst children and young adults, with patients frequently presenting with advanced disease. Delayed presentation may result from patients’ low socio-economic status and health education levels, and the paucity of health services in distant, isolated endemic areas. Overall, these factors lead to a devastating socio-economic impact [20, 21, 22, 23, 24]. Currently, the available treatments (combination antimicrobial therapy for actinomycetoma, or antifungal therapy for eumycetoma) have proved ineffective and expensive, with a range of side effects and high recurrence rate [25, 26]. Late presentations often necessitate amputation or destructive surgical excisions [27, 28, 29]. Patients require long-term follow-up to monitor recovery and recurrence, and unfortunately these factors as well as travel and opportunity cost of attending clinic lead to a high loss to follow up.

The disabling consequences of mycetoma are poorly understood. A medical literature search revealed no report addressing the present study objectives, and hence this study was designed to determine the disabling impact of mycetoma upon patients. We aim to identify key areas for future study with the ultimate goal of building evidence-based intervention and appropriate health care for those affected.

The mycetoma-related disability burden is hypothesised to be significant for several reasons. Firstly, the disease leads to structural impairment of the limbs, the most commonly affected parts, and disability arises from the direct loss of function. Secondly, current treatment options are limited and suboptimal, with disease potentially lasting for decades, resulting in
increasing impairments over time. Finally, support and adaptation for individuals with any disabling consequences of mycetoma are limited in Sudan, as indeed they are for many other disabling neglected conditions around the world.

As far as the authors know, this is the first-ever study of the disabling consequences of mycetoma.

**Material & methods**

**Study design**

The study was designed using the International Classification of Functioning, Disability and Health (ICF). The ICF is a standardized framework and classification for the description of health and health related states [30]. It conceptualises disability as an interaction between the patient health condition and his/her environment. Functions relate to body functioning (emotional state, pain, physical movement etc.), activities (driving, walking, etc.), and participation in society (engaging with religious ceremonies, etc.). Disability in this framework is a term for impairments or restrictions in functioning [31].

Study design, questions and qualifiers were taken directly from the ICF. Questions were selected based on their relevance to mycetoma and were purposefully broad, encompassing a range of possible impacts. All the possible questions in the ICF were reviewed; six questions from Body Functioning and 27 from Activities and Participation, thus 33 variables were selected. Answers to the questions were not ‘yes’ or ‘no’. Rather, grades of severity of the impairment or difficulty with a scale of mild, moderate, severe, or complete were used to further delineate the impact of the disease on individuals. These qualifiers for each grade were taken from the ICF (Table 1).

**Data collection**

The data was collected by four recently graduated doctors. Prior to the data collection, they had a four-day training course on data collection and interview skills provided by the first author. The training also included role-play, real-life interview assessment and an examination at the end of the course, following which their first two patients’ interviews were additionally observed for performance quality. They each passed the different parts of the training course.

The interviews were conducted each Monday at the Mycetoma Clinic of the Mycetoma Research Centre (MRC), University of Khartoum, between May 2016 and January 2017. To prevent selection bias, patients with confirmed mycetoma were given a number on arrival.

Table 1. Description of qualifiers.

| Qualifier                        | Description                                                                 | Score Given |
|----------------------------------|-----------------------------------------------------------------------------|-------------|
| No impairment or difficulty      | A person has no problem                                                     | 0           |
| Mild impairment or difficulty    | A problem that is present less than 25% of the time, with an intensity which a person can tolerate and which happens occasionally over the last 30 days | 1           |
| Moderate impairment or difficulty| A problem that is present less than 50% of the time, with an intensity which is interfering in a person’s day to day life and which happens occasionally over the last 30 days | 2           |
| Severe impairment or difficulty  | A problem that is present more than 50% of the time, with an intensity which is partially disrupting the person’s day to day life and which happens frequently over the last 30 days | 3           |
| Complete impairment or difficulty| A problem that is present more than 95% of the time, with an intensity which is totally disrupting to the person’s day to day life and which happens every day over the last 30 days | 4           |

https://doi.org/10.1371/journal.pntd.0007019.t001
Every third patient was chosen to be part of the study. Patients attended the clinic for their regular appointment and were interviewed either before or after their review. Patients who attended clinic Tuesday-Friday were not interviewed. We were able to survey 300 patients within the defined time scale of the project. Patients were given the option to decline and the interview was conducted in privacy. Ethical clearance was obtained from the Mycetoma Research Centre IRB and every patient gave verbal informed consent.

**Data analysis**

A scoring system for the various mycetoma-related disability variables studied was created. The variables included impairment in bodily functions or difficulty in activities and participation in society. A mild impairment or difficulty was given a value of one; that of moderate was given a value of two; severe was given a value of three, and complete inability to perform a given task or participate in activity was given a value of four. These values were added up over the 33 variables into a cumulative disability score that was used during data analysis. The statistical software used was Statistical Package for the Social Sciences and a P value of <0.05 denoted statistical significance. Correlations were determined using a Pearson co-efficient bivariate two-tailed test.

**Results**

**Demographic**

Between May 2016 and January 2017, 300 patients were interviewed; of these 228 (76%) were males and 72 (24%) were females with a gender ratio of 3:1. The mean age of the studied participants was 32.1 years with a sample standard deviation of 14.0 years; the youngest was 5 years old and the oldest was 74 years old; 39% of them were between the ages of 5–25 years, 49% between 26–50 years, and 12% were aged 51 to 74 years. The participants were most commonly students (16%), farmers (13%), and housewives (11.3%). In 36% of participants, the occupation was unspecified.

The mycetoma mean duration was 7.8 years with a sample standard deviation of 6.6 years and a range of three months to 34 years. 50% of participants had had mycetoma for 0–5 years, 23% for 5–10 years, and 27% for more than 10 years. Most individuals (270, 90%) reported a mycetoma lesion in the lower limb (hip through to toes), 23 patients (8%) had a mycetoma lesion in the upper limb, six patients (2%) reported the lesion in the head and neck, and one participant reported mycetoma in multiple sites. Most patients (203, 68%) had had local surgical excision (most frequently at rural hospital sites), of these 140 (69%) had had recurrence. Seven patients had undergone amputation, of whom two had had recurrence.

**Ethics statement**

Ethical clearance was obtained from the Mycetoma Research Centre IRB and every patient gave verbal informed consent. Written consent was decided to be not necessary as the patients’ identity was not disclosed in this article. The patients’ verbal informed consent acceptance was documented in each questionnaire during the interview.

**Cumulative disability scores**

The study showed that 49 (16.3%) of all participants had no difficulty or impairment in any of the 33 studied variables (Table 2). These patients were slightly younger, with a mean age of 29 years and an age range of 7 to 65; and they had had mycetoma for a shorter duration than the average (mean 6.9 years, range 0.5–20 years). Their most common occupations were students
(22%) or housewives (16%). All other patients (251, 83.7%) experienced disability ranging from mild to severe. The mean cumulative disability score for all degrees of disability among the studied patients was 10.7 with a range of 0 to 68. Most of the patients (133, 44.3%) had a score between 1 and 10. 62 patients (20.7%) had a score of 10–20, 31 patients (10.3%) had a score of 20–30, and 25 patients (8.3%) had a score of more than 30. The study showed that 181 patients (60.3%) had moderate impairment or difficulty in at least one domain variable. The scores were highest among farmers, those not in income-generating work, elderly patients and those with a longer disease duration.

Results by variable

In this study, 103 patients (34.3%) had local pain of various degrees at the mycetoma site (Table 3). Mild pain was confirmed by 70 patients (23.3%), 23 patients (8%) had moderate pain, and 10 (3%) had severe pain. Worsening of pain was statistically significantly correlated with advanced age; \( p < 0.01 \). No results are available for analgesic control in this population (Fig 1).

In this study, 119 patients (39.7%) reported walking difficulty, (Table 4): 54 patients (18%) had mild difficulty, 36 patients (12%) had moderate difficulty, 23 patients (8%) had severe difficulty, and six patients (2%) were completely unable to walk. Worsening of walking ability was statistically significantly associated with advanced age \( p < 0.01 \), longer disease duration \( p < 0.01 \), and pain at the lesion site \( p < 0.01 \).

In self-care, the activities that predominantly require upper limb mobility are least affected by mycetoma and score lowest (eating, drinking, etc.; Table 5). Impaired ability to self-dress was reported by 112 patients (38%): mild impairment in 86 patients (29%), moderate in 22 patients (7%), severe in three patients (1%) and complete in one patient (0.3%). Impairment inability to dress oneself was statistically significantly correlated to the presence of pain at the mycetoma site \( p < 0.01 \); but not with advanced patient age or longer duration of the mycetoma. Proportionally, most impairment in self-care is marked as mild (dressing 76.8%, washing 71.2%, toileting 74.6%; Fig 2).

| Table 2. Overall assessment of mycetoma disability using cumulative disability scoring. |
|---------------------------------|---|---|
| **Disability Scoring**          | **No.** | **%** |
| All patients                    |       |     |
| No difficulty/Impairment        | 49    | 16.3|
| Score of 1–10                   | 133   | 44.3|
| Score of 10–20                  | 62    | 20.7|
| Score of 20–30                  | 31    | 10.3|
| Above 30                        | 25    | 8.3 |
| Total                           | 300   | 100.0|

https://doi.org/10.1371/journal.pntd.0007019.t002

| Table 3. Impairments in body function. |
|----------------------------------------|
| **Degree of Impairment**               | **Energy and Drive** | **Sleep** | **Emotional** | **Body Image** | **Pain Sensation** | **Weight Maintenance** |
| None                                   | 220               | 269       | 224           | 216             | 197               | 236                     |
| Mild                                   | 52                | 18        | 47            | 37              | 70                | 46                      |
| Moderate                               | 26                | 11        | 28            | 42              | 23                | 17                      |
| Severe                                 | 01                | 02        | 01            | 03              | 10                | 01                      |
| Complete                               | 00                | 00        | 00            | 00              | 00                | 00                      |
| Missing records                        | 01                | 00        | 00            | 02              | 00                | 00                      |
| Total no. with some impairment         | 79                | 31        | 76            | 82              | 103               | 64                      |
| % with impairment                      | 26.4              | 10.3      | 25.3          | 27.5            | 34.3              | 21.3                     |

https://doi.org/10.1371/journal.pntd.0007019.t003
The study showed that 164 patients (55%) had difficulty in going about their daily life, (Table 6). A mild difficulty was reported by 63 patients (23%), 28 (9%) had moderate difficulty, 22 (7%) had severe difficulty, and 51 (17%) were completely unable to go about at least one aspect of their daily life because of the mycetoma. Many patients marked these sections as not applicable to them which was largely to do with male/female gender roles in domestic life. Generally speaking, in Sudan males are less likely to be involved in domestic life activities than females.

Table 4. Difficulties in mobility.

| Capacity          | Hand & Arm Use | Walking | Transportation | Driving |
|-------------------|----------------|---------|----------------|---------|
| No difficulty     | 273            | 181     | 214            | 93      |
| Mild Difficulty   | 19             | 54      | 47             | 09      |
| Moderate Difficulty| 05             | 36      | 19             | 01      |
| Severe Difficulty | 01             | 23      | 09             | 04      |
| Complete Inability| 01             | 06      | 04             | 14      |
| Missing records   | 01             | 00      | 00             | 00      |
| Not applicable    | 00             | 00      | 07             | 179     |
| Total no. With difficulty | 26            | 119     | 79             | 28      |
| % with impairment | 8.7            | 40.0    | 26.3           | 23.1    |

https://doi.org/10.1371/journal.pntd.0007019.t004
Table 5. Difficulties in self care.

| Capacity          | Washing | Toileting | Dressing | Eating | Drinking |
|-------------------|---------|-----------|----------|--------|----------|
| No difficulty     | 225     | 242       | 187      | 291    | 292      |
| Mild Difficulty   | 52      | 41        | 86       | 06     | 04       |
| Moderate Difficulty| 16      | 8         | 22       | 02     | 00       |
| Severe Difficulty | 02      | 02        | 03       | 00     | 00       |
| Complete Inability| 03      | 04        | 01       | 00     | 00       |
| Missing           | 00      | 02        | 00       | 00     | 01       |
| Not applicable    | 02      | 01        | 01       | 01     | 03       |
| Total no. with difficulty | 73   | 55        | 112      | 08     | 04       |
| % with impairment | 25.5    | 18.5      | 40.8     | 2.7    | 1.4      |

https://doi.org/10.1371/journal.pntd.0007019.t005

Fig 2. A patient carried consistently by his brother due to disability.

https://doi.org/10.1371/journal.pntd.0007019.g002
Regarding interpersonal relationships, 57 (19%) patients reported difficulty, (Table 7). Mild difficulty was reported by 33 patients (11%), 15 patients (5%) reported moderate difficulty, six patients (2%) reported severe difficulty and three patients (1%) reported a complete inability to relate in the area of interpersonal interaction.

Of the 300 interviewed patients, 37 were of school age (Table 8). Of these, 21 reported no difficulty at attending school while 16 reported present or previous difficulty. Twelve patients reported that mycetoma rendered them completely unable to continue their school education. Eighteen patients had the potential to gain higher education of whom seven experienced difficulty due to their mycetoma: four experienced mild difficulty, one experienced moderate difficulty, one experienced severe difficulty, and one was completely unable to continue their higher education because of their mycetoma. While the survey format did not allow us to collect information from all who reported that mycetoma had made continuing in school difficult or impossible, anecdotal comments to the data collectors identified mobility impairments that made walking to school difficult or impossible as the key barrier to continuing school attendance.

Using the ICF definition of ‘economic status’ as “having economic resources from any source enough to ensure economic security in the present and the future” in the study, 126 patients (46.7%) reported a reduction in their ability to economically sustain themselves because of their mycetoma (Table 9). Mild difficulty was reported by 47 patients (17%) in their ability to be economically self-sufficient because of their mycetoma, 36 patients (13%) reported moderate difficulty, 19 patients (7%) reported severe difficulty, and 24 patients (9%) were completely economically non-self-sufficient because of their mycetoma.

Specifically, 69 patients (40%) out of a relevant 173 patients found difficulty in their remunerative employment: 24 patients (14%) experienced mild difficulty, 10 patients (6%)...
moderate, six patients (4%) severe and 29 patients (17%) were completely unable to work for remunerative gain because of their mycetoma. There were 127 non-applicable individuals, who were not in work previously.

Impairment in remunerative employment was significantly correlated with the presence of pain \( (p<0.05) \), impairment in walking \( (p<0.01) \) and impairment in economic self-sufficiency \( (p<0.01) \). Impairment in economic self-sufficiency was also significantly correlated with the presence of pain \( (p<0.01) \) and impairment in walking \( (p<0.01) \) but also advanced age \( (p<0.01) \). Neither was correlated with duration of the mycetoma.

Of the 296 patients who reported that participation in a range of community activities were important to them, 63 (21.3%) experienced difficulty in participation because of the mycetoma, with 20 patients (7%) reporting mild, 22 patients (8%) moderate, and six patients (2%) severe limitations (Table 10). An additional 15 patients (5%) reported that they were completely unable to participate in community events or ceremonies. Of the 216 patients to whom recreation or leisure was important, 21 patients (9.7%) experienced difficulty. Of the 107 patients to whom sports were relevant, 68 patients (63.6%) experienced difficulty, of whom four patients (4%) experienced mild difficulty, six patients (6%) moderate difficulty, seven patients (7%) severe, and 51 (48%) reported being completely unable to participate in sports because of their mycetoma. Of this study population, 54 patients out of 290 (19%) experienced difficulty in socialising, whilst 71 patients out of 295 (24.1%) experienced difficulty in participating in religious activities (Fig 3).

**Discussion**

There is a general paucity of literature investigating the nexus of neglected tropical diseases and disability, though existing work supports our main findings. A study addressing leprosy-
related disability highlights the disease’s economic impact and association with extreme poverty. It also shows that people with a leprosy-related disability achieved fewer individual and family related objectives without interventions recognising their disability [32]. Work in malaria and tuberculosis also shows the importance of qualitative approaches in elucidating the nature of the disease-related disability, its interaction with poverty and related barriers to care [33, 34].

Our study is the first which measures and characterises mycetoma-related disability. It also clearly links mycetoma-related disability with a negative impact on economic livelihood. Overall, 83.7% of the studied patients report disability in one or more of the 33 ICF domains examined, with 60.3% reporting at least moderate disability in one or more domain. Further analysis reveals areas of differential impact along the lines of gender and age, alongside specific vulnerabilities common to all those with mycetoma, including pain, impaired mobility and stigma.

Four times as many males are diagnosed with this disease as females, suggesting variations either in incidence patterns or in societal responses, and hinting at gender-based vulnerabilities requiring further research. There may be true gender variation in disease incidence, relating to increased likelihood of traumatic injury allowing pathogenic inoculation, or to a hormonal influence on disease progression in males [35]. An alternative explanation is that women may be less likely to seek or receive medical care due to stigma, financial or ‘gender-role’ considerations, leading to reporting bias. This alternative is supported by a village level survey which showed that gender and age distributions were more evenly distributed than those measured at the tertiary level [15]. Indeed in endemic areas, females may in fact have similar risks of exposure as men, due to extensive outdoor activities. Either explanation hints at a particular vulnerability rooted in gender.

There are two striking age-related impacts. Firstly, older adults bear a greater burden of disability overall than younger patients or students, suggesting that symptoms may correlate with both disease duration, and therefore disease progression, and with physical activity and pain. Secondly, there is a strong effect on educational attendance in the school-age population where 44.4% of students with mycetoma experience difficulty in attending primary school, and 38.9% struggle to attend higher education. Our study did not formally assess this effect further, but physical inability to walk to school was mentioned by several interviewees as an underlying cause. For school-age children with little or no access to transport to school facilities, this would represent a strong barrier to accessing education. Illness and disease have also been shown to negatively impact a child’s learning and school time in less developed settings [36]. The combined effects of decreased access and poorer quality of learning when in lessons are likely to result in unfulfilled potential and loss of future opportunities.

| Capacity         | Ceremonies | Recreation & Leisure | Sports | Socialising | Religion |
|------------------|------------|----------------------|--------|-------------|----------|
| No difficulty    | 233        | 195                  | 39     | 236         | 224      |
| Mild Difficulty  | 20         | 09                   | 04     | 26          | 39       |
| Moderate Difficulty | 22       | 03                   | 06     | 10          | 24       |
| Severe Difficulty | 06         | 02                   | 07     | 8           | 3        |
| Complete Inability | 15       | 07                   | 51     | 10          | 05       |
| Missing          | 00         | 0                    | 0      | 0           | 00       |
| Not applicable   | 04         | 84                   | 193    | 10          | 05       |
| Total no. with some difficulty | 63 | 21                   | 68     | 54          | 71       |
| No. with impairment % | 21.3 | 9.7                  | 63.6   | 18.6        | 24.1     |

https://doi.org/10.1371/journal.pntd.0007019.t010
Three further mycetoma-related effects are worth discussing for their creation of particular vulnerabilities common to all individuals with the disease. These include pain, limited mobility and stigma. Mycetoma is typically characterised as a painless disease, although there are reports of local pain at the mycetoma site and that is frequently due to secondary bacterial infection [37, 38, 39]. However, in this study over a third of respondents (103 patients, 34.3%) reported local pain, higher than has been previously reported [2, 4, 20]. Whilst most cases were mild, infrequent and tolerable, this challenges the idea that mycetoma is generally painless. It is likely to result in vulnerabilities correlating with poorer development and achievement outcomes including school attendance, academic performance and the ability to perform physical tasks, both domestic and professional.
Walking itself receives high impact scores with 119 patients (40.0%) complaining of restriction in their ability to walk without assistance. The assessment questions point towards impairment being produced by the mycetoma itself, rather than other co-morbidities or age-associated frailties. In general, co-morbidities are rare in mycetoma as most of the patients by number are young adults and children (though notably those with the most disabling consequences are the elder patients). The associations between a sedentary lifestyle and non-communicable diseases are well-known however and those with mycetoma-related physical restriction are likely to be at increased risk for them.

A substantial number of respondents reported reduced participation in education, community, religious, social and civic life. This could be partly a result of stigma and social isolation, either because of specific beliefs about the disease e.g. contagion, linkage of physical and spiritual malady, or due to broader prejudice against individuals with a disability.

However, less than 20% of respondents reported difficulties in socialising (18.6%), with just 7% reporting difficulties in interpersonal relationships overall. Furthermore, relatively few patients had impairments in such bodily functions as energy and drive (26%), emotional function (25%) or body image impairment (27.5%). These findings might be explained by the localised, slowly progressive nature of the disease, together with the rarity of cosmetically ‘significant’ areas, such as the face, being affected.

It is also interesting to note that few patients had impairment in informal social- (11%), family- (5%) or intimate- (6%) relationships. This may be a finding particular to the study setting, partly related to the strong concept of the extended families in the Sudan, where patients receive support and care from many family members even if they are not close relatives.

Overall these findings suggest that in the context of Sudan reduced participation in aspects of public life may be influenced as much by physical issues as by social stigma. Further work is needed to explore this complex area.

The most common limitation, by a number of people affected, was in economic self-sufficiency (126 affected, 46.8% of applicable patients). Self-sufficiency here was defined as having enough economic resources from any source to ensure economic security in the present and the future [30]. A component of this is likely to be disease-related inability to work. Indeed 40% of those who would otherwise be in work were partially or completely unable to engage in remunerative employment because of their mycetoma. Our results do not explore the exact nature of this loss in economic self-sufficiency, however we know that even where treatment is available free of charge, such as that provided at the MRC, indirect healthcare costs (e.g. cost of transport, loss of paid work) are consistently a significant burden on household economies [40]. An emerging body of research evidence also shows that individuals living with a disability, and households with disabled members, face increased costs compared to those without, e.g. for medical care, transportation, loss of paid work both by the affected individual and by those who remain at home to provide care [41,42].

In this study, there were four main limitations. Firstly, data collection was based on the ICF Model, rather than the Washington Group (WG) Questions on Disability Statistics [43]. This was because the project was initiated and data was collected prior to awareness of the WG methodology by field research staff. There is some overlap, since the WG questions are based upon the ICF Model, however the WG methodology captures dimensions of individual functioning more precisely and should be the basis of future work. Nevertheless, we believe our data remains valid, relevant and yields new insight into mycetoma-related disability. Secondly, data collectors were recent medical graduates without backgrounds in research or disability. Therefore extensive training and support was given to minimise the risk of decreased accuracy or reliability of results. Third, our data is predominantly quantitative, save for anecdotes reported to data collectors. A qualitative component in further research could add further
valuable insight into how individuals and societies are affected. And finally, although this was not the purpose of the study, we did not record whether patients had actinomycetoma or eumycetoma and are unable to perform a subgroup analysis of these groups to look for differences in disability.

In conclusion, this is the first study to outline the burden of disability caused by mycetoma. It shows clear evidence of mycetoma-related impact on individuals’ body function, mobility, and ability to self-care, with significant ramifications for domestic life, interpersonal relationships, educational attainment, economic status, and civic engagement. There is sufficient evidence to support specific interventions aiming to mitigate and adapt to the disabling consequences of mycetoma. However, better detection and disease education are also important for preventing infection and the development of mycetoma-related disability.

Clinically, effective pain management should be routinely integrated into mycetoma services, particularly for those groups identified as higher risk such as farmers and older adults. Different analgesic agents can be evaluated for efficacy against mycetoma-related pain. More definitive treatment should include the elimination of the secondary bacterial infection by appropriate anti-pathogenic agents and repeated lesion debridement. Further addition of physiotherapy services could begin to address limitations of mobility and function. Simple walking aids could be a starting point followed by in-house physiotherapy services. They could also provide a starting point for reducing risks associated with sedentary lifestyles.

In education, services could include assessment of a student’s mycetoma-related disability using a pragmatic screening tool based on our results. This would inform adaptations in educational provision, including greater local awareness and consideration of learning aids or adaptations that allow distance learning, participation in physical and sporting activities, in modifying transport to and from school as well as mitigating stigma in educational settings.

This study shows evidence of impaired revenue generation at an individual level and a negative impact on economic self-sufficiency and household income. While this establishes that diseases such as mycetoma have significant development and public health implications, further research is needed to quantify its financial effects at the individual, household and societal levels. This includes effects on revenue generation, career opportunities and health-related costs, including the reallocation of disposable assets.

Above all, our data emphasise that the multi-faceted, long-term disabling consequences of NTDs, such as mycetoma, must not be overlooked. Their effects are likely to be felt at the level of individuals, families and communities, across multiple social and economic dimensions. Importantly, such effects are likely to be modifiable and therefore must be considered and addressed in future policy and programming.

**Author Contributions**

**Conceptualization:** Mustafa Abbas, Peter Siordet Scolding, Abubaker Ahmed Yosif, Roa Fath EL Rahman, Melka O. EL-Amin, Mohamed Kamal Elbashir, Nora Groce, Ahmed Hassan Fahal.

**Data curation:** Abubaker Ahmed Yosif, Roa Fath EL Rahman, Melka O. EL-Amin, Mohamed Kamal Elbashir, Nora Groce, Ahmed Hassan Fahal.

**Formal analysis:** Mustafa Abbas, Peter Siordet Scolding, Abubaker Ahmed Yosif, Mohamed Kamal Elbashir, Nora Groce, Ahmed Hassan Fahal.

**Investigation:** Roa Fath EL Rahman.

**Methodology:** Mustafa Abbas, Ahmed Hassan Fahal.
Project administration: Ahmed Hassan Fahal.

Supervision: Mustafa Abbas, Peter Siordet Scolding, Nora Groce.

Validation: Mustafa Abbas, Ahmed Hassan Fahal.

Visualization: Mustafa Abbas, Abubaker Ahmed Yosif, Roa Fath EL Rahman, Melka O. EL-Amin, Mohamed Kamal Elbashir, Nora Groce.

Writing – original draft: Mustafa Abbas, Peter Siordet Scolding, Abubaker Ahmed Yosif, Roa Fath EL Rahman, Melka O. EL-Amin, Mohamed Kamal Elbashir, Nora Groce, Ahmed Hassan Fahal.

Writing – review & editing: Mustafa Abbas, Peter Siordet Scolding, Abubaker Ahmed Yosif, Roa Fath EL Rahman, Melka O. EL-Amin, Mohamed Kamal Elbashir, Nora Groce, Ahmed Hassan Fahal.

References
1. van de Sande W, Fahal A, Ahmed SA, Serrano JA, Bonifaz A, et al. (2018) Closing the mycetoma knowledge gap. Med Mycol. Apr 1; 56(suppl_1):153–164. https://doi.org/10.1093/mmy/myx061 PMID: 28992217

2. Fahal AH. (2004) Mycetoma thorn on the flesh. Trans R Soc Trop Med Hyg. 98(1):3–11. PMID: 14702833

3. Fahal AH, Hassan MA. (1992) Mycetoma. Br J Surg. 79(11): 1138–1141. PMID: 1467883

4. Bonifaz A, Tirado-Sánchez A, Calderón L, Saúl A, Araiza J, et al. (2014) Mycetoma: experience of 482 cases in a single center in Mexico. PLoS Negl Trop Dis. 21; 8(8):e3102.

5. Ahmed AO, van Leeuwen W, Fahal A, van de Sande W, Verbrugh H, et al. (2004) Mycetoma caused by Madurola mycetomatis: a neglected infectious burden. Lancet Infect Dis. 4(9):566–74. https://doi.org/10.1016/S1473-3099(04)01131-4 PMID: 15336224

6. Fahal AH. (2011) Mycetoma in Richard, Guerrant, Walker, Peter, Tropical Infectious Diseases: Principles, Pathogens and Practice. Third edition, Elsevier Publisher, 83, pp 565–568.

7. Fahal AH. (2013) Mycetoma in Williams, Bulstrode, O’Connell, Bailey and Love’s Short Practice of Surgery 26E: 26th Edition, Oxford University Press, pp 84–88.

8. Hassan MA, Fahal AH. (2004) Mycetoma: in Tropical Surgery, Kamil R, Lumbly J, Westminster Publication LTD, pp 30–45.

9. López-Martínez R, Méndez Tovar LJ, Lavalle P, Welsh O, Saúl A, (1992) Epidemiology of mycetoma in Mexico: study of 2105 cases. Gac Med Mex. 128(4):477–81. PMID: 1308000

10. López-Martínez R, Méndez-Tovar LJ, Lavalle P, Welsh O, Saúl A, (1992) Epidemiology of mycetoma in Mexico. A review of 3933 cases. Gac Med Mex. 149(5):586–92. PMID: 24108347

11. Ahmed AOA, Adelmann D, Fahal AH, Verbrugh HA, Van Belkum A, et al. (2002) Environmental occurrence of Madurola mycetomatis, major agent of human eumycetoma in Sudan. J Clin Microbiol. 40(3): 1031–1036. https://doi.org/10.1128/JCM.40.3.1031-1036.2002 PMID: 11880433

12. Ahmed AOA, van de Sande WW, Fahal A, Bakker-Woudenberg I, Verbrugh H, et al. (2007) Management of mycetoma: major challenge in tropical mycoses with limited international recognition. Curr Opin Infect Dis. 20(2):146–51. https://doi.org/10.1097/QCO.0b013e32803d38fe PMID: 17496572

13. van Belkum A, Fahal AH, van de Sande WW. (2012) Mycetoma by Madurola mycetomatis: A completely neglected medico-social dilemma. In Hot Topics in Infection and Immunity in Children IX. Springer Science & Business Media, New York.

14. Bakheit SM, Fahal AH, Musa AM, Mohamed ESW, Omer RF, Ahmed ES, et al. (2018) A holistic approach to the mycetoma management. PLoS Negl Trop Dis 12(5): e0006391. https://doi.org/10.1371/journal.pntd.0006391 PMID: 29746460

15. Fahal A, Mahgoub ES, EL Hassan AM, Abdel-Rahman ME, Alshambaty Y, et al. (2014) A New Model for Management of Mycetoma in the Sudan. PLoS Negl Trop Dis 8(10): e3271.

16. Hay RJ, Fahal AH. (2015) Mycetoma: an old and still neglected tropical disease. Trans R Soc Trop Med Hyg. 109(3):169–70. https://doi.org/10.1093/trstmh/trv003 PMID: 25667234

17. Lynch JB. (1964) Mycetoma in the Sudan. Ann R Coll Surg Engl. 35: 319–340. PMID: 14248320

18. Aounallah A, Boussofara L, Ben Said Z, Ghariani N, Saidi W, et al. (2013) Analysis of 18 Tunisian cases of mycetoma at the Sousse hospital (1974–2010). Bull Soc Pathol Exot. 106(1): 5–8. https://doi.org/10.1007/s13149-012-0233-1 PMID: 22552715
19. Nenoff P, van de Sande WW, Fahal AH, Reinel D, Schöfer H. (2015) Eumycetoma and actinomycetoma—an update on causative agents, epidemiology, pathogenesis, diagnostics and therapy. J Eur Acad Dermatol Venereol. 29(10):1873–83. https://doi.org/10.1111/jdv.13008 PMID: 25726758

20. Fahal AH EL Hassan AM, Mahgoub ES, Rahman ME. (2015) Mycetoma in the Sudan: The Mycetoma Research Centre Update. PLoS Negl Trop Dis. Mar 27; 9(3):e0003679. eCollection 2015 Mar. https://doi.org/10.1371/journal.pntd.0003679

21. Hala Taha, Ahmed Fahal, van de Sande Wendy WJ. (2015) Mycetoma: Epidemiology, Treatment Challenges and Progress. Mycetoma: epidemiology, treatment challenges and progress. Res Rep Trop Med. 6; 30–36.

22. van de Sande WW, Mahgoub ES, Fahal AH, Goodfellow M, Welsh O, et al. (2014) The Mycetoma Knowledge Gap: Identification of Research Priorities. PLoS Negl Trop Dis. 2014 Mar 27; 8(3):e2667. https://doi.org/10.1371/journal.pntd.0002667 eCollection 2014 Mar PMID: 24675533

23. Fahal AH, Shaheen S, Jones DH. (2014) The orthopaedic aspects of mycetoma. Bone Joint J 96-B: 420–425. https://doi.org/10.1302/0301-620X.96B3.31421 PMID: 24589802

24. Welsh O, Al-Abdely HM, Salinas-Carmona MC, Fahal AH. (2014) Mycetoma Medical Therapy. PLoS Negl Trop Dis 8(10): e3218. https://doi.org/10.1371/journal.pntd.0003218 PMID: 25330342

25. Welsh O, Vera-Cabrera L, Welsh E, Salinas MC. (2012) Actinomycetoma and advances in its treatment. Clin Dermatol. 30: 372–381. https://doi.org/10.1016/j.clindermatol.2011.06.027 PMID: 22682184

26. Mahgoub ES, Gumaa SA. (1984) Ketoconazole in the treatment of eumycetoma due to madurella mycetomatis. Trans R Soc Trop Med Hyg. 78: 376–379. PMID: 6087513

27. Fahal AH, Rahman IA, El-Hassan AM, Rahman ME, Zijlstra EE. (2011) The safety and efficacy of itraconazole for the treatment of patients with eumycetoma due to Madurella mycetomatis. Trans R Soc Trop Med Hyg 105: 127–132. https://doi.org/10.1016/j.trstmh.2010.11.008 PMID: 21247608

28. Zein HA, Fahal AH, Mahgoub el S, El Hassan TA, Abdel-Rahman ME. (2012) Predictors of cure, amputation and follow-up dropout among patients with mycetoma seen at the Mycetoma Research Centre, University of Khartoum, Sudan. Trans R Soc Trop Med Hyg. 106: 639–644. https://doi.org/10.1016/j.trstmh.2012.07.003 PMID: 22854685

29. Suleiman SH, Wadael la ES, Fahal AH. (2016) The Surgical Treatment of Mycetoma. PLoS Negl Trop Dis 10(6): e0004690. https://doi.org/10.1371/journal.pntd.0004690 PMID: 27336736

30. International Classification of Functioning, Disability and Health. (2001) Geneva : World Health Organisation.

31. Towards a Common Language for Functioning, Disability and Health. (2002) Geneva: World Health Organisation.

32. Bowers B, Singh S, Kuipers P. (2014) Responding to the challenge of leprosy-related disability and ultra-poverty. Lepr Rev. 85(3):141–8. PMID: 25509714

33. Ingstad B, Munthali AC, Braathen SH, Grut L. (2012) The evil circle of poverty: a qualitative study of malaria and disability. Malaria journal. 11:15. https://doi.org/10.1186/1475-2875-11-15 PMID: 22236358

34. Grut L, Sanudi L, Braathen T, Eide AH. (2015) Access to tuberculosis services for individuals with disability in rural Malawi, a qualitative study. PloS one. 10(4):e0122748. https://doi.org/10.1371/journal.pone.0122748 PMID: 25830950

35. Zijlstra EE, van de Sande WWJ, Welsh O, Mahgoub ES, Goodfellow M, et al. Mycetoma: a unique neglected tropical disease. Lancet Infect Dis 2016; 16: 100–12 https://doi.org/10.1016/S1473-3099(15)00359-X PMID: 26738840

36. Glewwe P, Miguel EA. The Impact of Child Health and Nutrition on Education in Less Developed Countries. In: Schultz TP, Strauss JA, editors. Handbook of Development Economics 42007. p. 3561–606.

37. Bowers MJ, Diaz L, Reddy S, Kraus EW, Fernandez M. (2011) Painful swollen foot. Mycetoma (Madura foot). Arch Dermatol. 147(5):609–14. https://doi.org/10.1001/archdermatol.2011.90-a PMID: 21576582

38. Ahmed AOA, Fahal AH, Abugroun EAM, Zijlstra E, Belkum A van, et al. (1998) Unexpected high prevalence of secondary bacterial infection in mycetoma. J Clin Microbiol. 36(3): 850–851. PMID: 9508332

39. Goopota S, Ali I, Singh G, Mishra RN. (2013) Mycetoma foot. J Family Community Med. May; 20(2):136–8. https://doi.org/10.4103/2230-8229.114775 PMID: 23983567

40. World Health Organisation Guide to Identifying the Economic Consequences of Disease and Injury. (2009) Geneva: World Health Organisation.

41. Banks LM, Polack S. (2015) The Economic Costs of Exclusion and Gains of Inclusion of People with Disabilities: Evidence from Low and Middle-Income Countries. London: International Centre for Evidence in Disability, London School of Hygiene & Tropical Medicine
42. Mitra S, Palmer M, Kim H, Mont D, Groce N. (2017) Extra costs of living with a disability: A review and agenda for research. Disabil Health J. Oct; 10(4):475–484. https://doi.org/10.1016/j.dhjo.2017.04.007 PMID: 28501322

43. Washington Group on Disability Statistics. National Center for Health Statistics. [Online]. Last viewed 31.10.2018. URL: www.washingtongroup-disability.com